Assort Health Closes at $76 Mn for Its Agentic AI Platform at Series B Funding

Healthtech startup Assort Health has raised $76 million in Series B funding, led by Lightspeed Venture Partners with investments by Felicis, First Round Capital, Chemistry, A*, Liquid2, and Quiet Capital.

So far, the company has raised $102 million following its Series A funding.

The fund is aimed at accelerating the development and deployment of Assort OS, the company’s agentic AI platform designed to transform patient engagement across the healthcare ecosystem.

Reportedly, Galym Imanbayev, partner at Lightspeed Venture Partners, will join the board, and Paul Ricci, founding CEO of Nuance, will join as a board advisor.

About Assort Health

Assort OS leverages speciality-specific AI agents to handle a wide range of patient interactions across voice, text, and web channels, including appointment scheduling, care navigation, prescription refills, physician referrals, and lab test coordination.

By automating these touchpoints, Assort Health aims to enhance patient experiences, reduce administrative burdens for providers, and streamline healthcare operations.

Commenting on the launch, Jon Wang, founder and co-CEO of Assort Health," At Assort Health, we are leveraging agentic AI to revolutionise the way provider practice and hospitals engage with patients to remove barriers to care."

"Launching our comprehensive platform, Assort OS, we are bringing customers an opportunity to up-level operations and making it easier to get patients in the door," added Jeffery Liu, founder and co-CEO of Assort Health.

Further, speaking of his thoughts, Imanbayev of Lightspeed Venture Partners, "We are thrilled to back Assort Health as it leads the re-platforming of patient engagement into the AI-native era with superior experience for patients and unprecedented outcomes for the organizations that care for them."

Stay tuned for more such updates on Digital Health News